Estrella Immunopharma, Inc.
ESLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001844417
No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.99M in total; no superinvestor holds it.
Other share classesESLAW
13F holders, Q2 2025
Institutional positions in Estrella Immunopharma, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- 0 vs. Q1 2025
- Shares held
- 634.8K
- +21.7K (+3.5%) vs. Q1 2025
- Total value
- $559.6K
- −$8.90K (−1.6%) vs. Q1 2025
- New holders
- 1
- 5 more added
- Sold out
- 1
- 2 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ESLA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 15 | $4.99M |
| Q1 2026 | 16 | $5.49M |
| Q4 2025 | 15 | $1.56M |
| Q3 2025 | 13 | $878.8K |
| Q2 2025 | 11 | $559.6K |
| Q1 2025 | 11 | $568.4K |
| Q4 2024 | 11 | $341.1K |
| Q3 2024 | 10 | $232.1K |
| Q2 2024 | 7 | $129.2K |
| Q1 2024 | 6 | $165.5K |
| Q4 2023 | 7 | $143.2K |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Estrella Immunopharma, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 282,843 | $242.4K | 0.00% | +5,265+1.9% | Added |
| Geode Capital Management, LLC | 103,337 | $88.5K | 0.00% | +3,164+3.2% | Added |
| UBS Group AG | 72,773 | $69.9K | 0.00% | +31,739+77.3% | Added |
| Citadel Advisors LLC | 50,156 | $43.0K | 0.00% | −41,443−45.2% | Reduced |
| Atw Spac Management LLC | 40,000 | $38.4K | 0.06% | 00.0% | Unchanged |
| BlackRock, Inc. | 31,407 | $30.2K | 0.00% | +6,754+27.4% | Added |
| State Street Corp | 22,352 | $19.1K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 17,266 | $14.0K | 0.00% | +17,266 | New |
| Maso Capital Partners Ltd | 10,000 | $9.60K | 0.02% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 4,593 | $4.41K | 0.00% | −1,053−18.7% | Reduced |
| Bank of America Corp | 92 | $89 | 0.00% | +5+5.7% | Added |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −23−100.0% | Sold out |